“casdin-capital” Archives

in
Entry Author Date Location
Monte Rosa Raises $96M for “Glue-Based” Protein Degrading Drugs 09/24/20 Boston
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More 09/04/20 National
Tango Therapeutics Adds $175M, Deal Turns Partner Gilead Into Investor 08/17/20 Boston
Thrive Adds $257M, Plans Pivotal Trial of Early Cancer Detection Test 07/29/20 National
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later 06/30/20 Boston
Invitae Makes a Precision Oncology Push With $886M Deal for ArcherDx 06/22/20 San Francisco
Sarepta Inks Codiak Deal to Explore Combining Exosomes, Muscle Meds 06/22/20 Boston
Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes 06/11/20 Boston
Insitro Adds $143M to Fuel Machine Learning-Driven Drug Development 05/26/20 San Francisco
Tango Adds $60M in CRISPR Hunt for Synthetically Lethal Cancer Drugs 04/09/20 Boston
Kallyope Gains $112M to Move “Gut-Brain Axis” Programs to the Clinic 03/25/20 New York
Amunix Raises $73M to Bring Safer T Cell Engagers to Solid Tumors 03/04/20 San Francisco
Generation Bio Pockets $110M for Next Wave of Gene Therapy, IPO Plans 01/13/20 Boston
After Amgen’s Spark, Revolution Med Nabs $100M to Push RAS Cancer Drugs 07/09/19 San Francisco
Vividion Raises $82M to Advance Small Molecule Drugs to the Clinic 04/30/19 San Diego
With $191M Haul, Maze Therapeutics Takes Aim at Genetic Diseases 02/28/19 San Francisco
Relay Raises $400M to Kick Protein Motion Drug R&D into High Gear 12/20/18 Boston
Genomatica Grabs $90M to Boost Sustainable Chemical Business 10/05/18 San Diego
Alector Snags $133M to Activate Immune Cells Against Neurodegeneration 07/25/18 San Francisco
Raising $56M, Revolution Medicines Drops Old Work and Turns to Cancer 04/24/18 San Francisco
Fresh Off $25M Raise, Generation Adds $100M For Next-Gen Gene Therapy 02/27/18 Boston
Relay Tx Raises $63M to Advance Protein Motion Drugs Into the Clinic 12/14/17 Boston
VCs Put More Dollars Into Exosomes as Codiak Bio Lands $76M 11/29/17 Boston
23andMe Raises $250M For Consumer Disease-Risk Tests, Drug R&D 09/12/17 San Francisco
Eyeing First Trials, Syros Brings in $40M and More Crossovers 01/13/16 Boston
Syros Pharmaceuticals Garners $40,000,000 New Financing 01/13/16 Boston
Flatiron Health Lands $175,000,000 Series C Financing 01/06/16 New York
Cancer Vaccines Back in Vogue as VCs Put $102M Into Gritstone Oncology 10/20/15 San Francisco
23andMe Garners $115,000,000 Series E Financing 10/14/15 San Francisco
At Summer’s End, Can Crossover Winds Stay At Biotech’s Back? 09/01/15 National
Page 1 of 2 next page »